Indivior Pharmaceuticals, Inc. (INDV) fundamentals score
Indivior Pharmaceuticals, Inc. and its subsidiaries is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 6.8 out of 10, Mixed fundamentals
- Growth: 7.9/10
- Profitability: 7.5/10
- Financial health: 7.2/10
- Earnings quality: 4.1/10
- Valuation: 5.8/10
Scores are calculated from Indivior Pharmaceuticals, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10